These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 2658097)

  • 1. Biomodulation effects of extracorporeal circulation in apheresis.
    Malchesky PS; Nosè Y
    Semin Hematol; 1989 Apr; 26(2 Suppl 1):42-51. PubMed ID: 2658097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pediatric therapeutic apheresis: rationale and indications for plasmapheresis, cytapheresis, extracorporeal photopheresis, and LDL apheresis.
    Kim YA; Sloan SR
    Pediatr Clin North Am; 2013 Dec; 60(6):1569-80. PubMed ID: 24237988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The lipid- and lipoprotein- [LDL-Lp(a)] apheresis techniques. Updating.
    Stefanutti C; Morozzi C; Perrone G; Di Giacomo S; Vivenzio A; D'Alessandri G
    G Chir; 2012; 33(11-12):444-9. PubMed ID: 23140934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunomodulation: bioengineering aspects.
    Malchesky PS
    Artif Organs; 1986 Apr; 10(2):128-34. PubMed ID: 3487303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of hemorrhagic complications in plasmapheresis without extracorporeal circuit anticoagulation, in children.
    Fernández Sarmiento J; Varela MA; Pinzón CE
    Transfus Apher Sci; 2016 Aug; 55(1):136-40. PubMed ID: 27177490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A comparative and technical assessment of the HELP system (heparin extracorporeal LDL precipitation) and cascade filtration (CF) for the treatment of high plasma lipids].
    Loschiavo C
    G Ital Nefrol; 2013; 30(3):. PubMed ID: 23832475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quo vadis haemapheresis. Current developments in haemapheresis.
    Borberg H
    Transfus Apher Sci; 2006 Feb; 34(1):51-73. PubMed ID: 16412691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoadsorption, current status and future developments.
    Braun N; Bosch T
    Expert Opin Investig Drugs; 2000 Sep; 9(9):2017-38. PubMed ID: 11060790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood detoxification by membrane plasma filtration.
    Malchesky PS; Horiuchi T; Usami M; Emura M; Nose Y
    Int J Artif Organs; 1986 Sep; 9(5):349-54. PubMed ID: 3781668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel approach to the treatment of chronic fluid overload with a new plasma separation device.
    Ronco C; Ricci Z; Bellomo R; Bedogni F; Handley H; Gorsuch R; Levin N
    Cardiology; 2001; 96(3-4):202-8. PubMed ID: 11805388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LDL-apheresis with the HELP system: a 16-month study in severe hypercholesterolemic patients with ischemic heart disease.
    Baggio G; Previato L; Corti C; Bilato C; Belloni M; Ongaro G; Crepaldi G
    Beitr Infusionsther; 1988; 23():146-51. PubMed ID: 2484770
    [No Abstract]   [Full Text] [Related]  

  • 12. The selective therapeutic apheresis procedures.
    Sanchez AP; Cunard R; Ward DM
    J Clin Apher; 2013 Feb; 28(1):20-9. PubMed ID: 23420592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Beneficial characteristics of protease inhibitor as an anticoagulant for extracorporeal circulation].
    Akizawa T
    Rinsho Ketsueki; 1990 Jun; 31(6):782-6. PubMed ID: 2214168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Russian pioneers of therapeutic hemapheresis and extracorporeal hemocorrection: 100-year anniversary of the world's first successful plasmapheresis.
    Sokolov AA; Solovyev AG
    Ther Apher Dial; 2014 Apr; 18(2):117-21. PubMed ID: 24571429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasmapheresis and other extracorporeal filtration techniques in critical patients.
    Daga Ruiz D; Fonseca San Miguel F; González de Molina FJ; Úbeda-Iglesias A; Navas Pérez A; Jannone Forés R
    Med Intensiva; 2017 Apr; 41(3):174-187. PubMed ID: 28062169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical considerations for planning a therapeutic apheresis procedure.
    Shelat SG
    Am J Med; 2010 Sep; 123(9):777-84. PubMed ID: 20541168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are selective macromolecule removal plasmapheresis systems useful for autoimmune diseases or hyperlipidemia?
    Malchesky PS; Kaplan A; Koo AP; Sakurada Y; Siami GA
    ASAIO J; 1993; 39(4):868-72. PubMed ID: 8123919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Extracorporeal methods for low-density lipoprotein apheresis in treating patients with severe forms of hereditary hypercholesterolemia. A review].
    Konovalov GA
    Ter Arkh; 1991; 63(10):111-9. PubMed ID: 1805407
    [No Abstract]   [Full Text] [Related]  

  • 19. Correction of hyperviscosity by apheresis.
    Zarkovic M; Kwaan HC
    Semin Thromb Hemost; 2003 Oct; 29(5):535-42. PubMed ID: 14631553
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.